Antiglycolytic Agent Stabilization for Glucose Sensor Accuracy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional glucose monitoring devices for diabetics suffer from transient, low spurious readings, particularly after sensor placement, due to blood clots consuming glucose, leading to inconvenient delays and frequent calibrations.
Innovation Solution
Electrochemical analyte sensors incorporating an antiglycolytic agent, such as L-glyceraldehyde, and a chelating agent like borate minerals or boric acid, positioned proximate to the working electrode to stabilize the antiglycolytic agent and prevent glucose consumption by clots, minimizing spurious readings.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Extent of automation
If a subcutaneous glucose sensor is inserted into the body, then continuous glucose monitoring is enabled, but spurious low readings occur due to blood clots consuming glucose
Solution Approach 1:
The patent applies preliminary anti-action by incorporating an antiglycolytic agent into the sensor that preemptively prevents glucose consumption by blood clots. The agent is released upon sensor insertion to inhibit glycolysis in the forming clot, thereby preventing the spurious low readings before they occur. This resolves the contradiction by maintaining continuous monitoring capability while eliminating the measurement precision problem caused by clot-mediated glucose consumption.
2Measurement precision
If an antiglycolytic agent is added to prevent glucose consumption by clots, then spurious readings are reduced, but the antiglycolytic agent degrades over time
Solution Approach 1:
The patent uses a chelating agent as an intermediary substance that binds to the antiglycolytic agent and stabilizes it against degradation. The chelating agent forms a protective complex with the antiglycolytic agent, preventing its breakdown over time while allowing it to maintain its antiglycolytic activity. This resolves the contradiction by extending the stability of the antiglycolytic agent while preserving its ability to reduce spurious readings.
3Measurement precision
If spurious low readings occur during the first hours after sensor placement, then accurate monitoring is delayed, but frequent calibration is required
Solution Approach 1:
The patent applies preliminary action by having the antiglycolytic agent act immediately upon sensor insertion to prevent glucose consumption by clots during the critical initial period. This preliminary prevention of glycolysis ensures that accurate readings can be obtained shortly after sensor placement without requiring frequent calibrations, thereby reducing the time loss associated with calibration while maintaining measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables immediate and accurate glucose monitoring with reduced calibration requirements and minimal spurious readings, providing clinically reliable data shortly after sensor placement without significant interruptions.
Implementation Method 1
a chelating agent that stabilizes the antiglycolytic agent positioned proximate to the working electrode of the sensor
Implementation Method 2
an antiglycolytic agent or a precursor thereof... capable of preventing degradation of the antiglycolytic agent
Implementation Method 3
electrochemical analyte sensors having an antiglycolytic agent or a precursor thereof and a chelating agent that stabilizes the antiglycolytic agent positioned proximate to the working electrode of the sensor
Data Source
AI summary
An analyte sensor including an antiglycolytic agent or a precursor thereof and a chelating agent that stabilizes the antiglycolytic agent positioned proximate to the working electrode of the sensor. Also provided are systems and methods of using the electrochemical analyte sensors in analyte monitoring.